13 patents
Utility
CD73 inhibitors and uses thereof
28 Feb 23
Bin Wang, Hanbiao Yang, Karl Bedke, Paul Wehn, James P. Rizzi
Filed: 4 Jun 21
Utility
Pyrazolesulfonamides As Antitumor Agents
26 May 22
Compounds of formula I, that induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity are described herein.
Michelle Ann Estrada, Jonas Grina, Paul Wehn, Rui Xu
Filed: 6 Apr 20
Utility
dntu8nj84dt2ontqwtcboy03zi1oaoudu ouv9cai5psmlnapmtl
17 Mar 22
This application discloses methods for the synthesis of substituted indane analogs that modulate HIF-2α activity, as well as key intermediates produced thereby.
Peter J. Stengel, Rui Xu, Stacey Renee Spencer
Filed: 11 Sep 20
Utility
v8ej6gk6g9us a3jqzt3yk4w2
16 Dec 21
Provided herein are solid dispersions comprising a HIF-2α inhibitor, pharmaceutical compositions comprising the solid dispersions, and methods for treating HIF-2α-mediated diseases and conditions.
Christopher Lindemann, Peter J. Stengel
Filed: 23 Oct 19
Utility
xwnmk1auw7fd7e9u6zxnbdzes6bri ynlwv28es0
14 Oct 21
Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
Bin Wang, Hanbiao Yang, Karl Bedke, Paul Wehn, James P. Rizzi
Filed: 4 Jun 21
Utility
1wo1j1islus mqy3mb7jmpzzig67okdwgcsjgcojk
19 Aug 21
Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
Bin Wang, Hanbiao Yang, Karl Bedke, James P. Rizzi, Heli Huang, Keshi Wang
Filed: 31 May 19
Utility
rmy47x ry4h55wft1xksb4su6osookxwdeqrnws6sq7dlvte00hka9vliq
21 Jan 21
The present disclosure provides methods of reducing inflammation of the digestive system in a subject in need thereof, including subjects suffering from inflammatory bowel disease.
John A. Josey, Rajeev Shrimali, Eli M. Wallace, Tai Wong
Filed: 27 Mar 19
Utility
atnvgf22tfu5gu qahzx6glv1
19 Oct 20
Disclosed herein are substituted indane derivatives useful as HIF-2α inhibitors.
Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
Filed: 3 Mar 16
Utility
em1isuthguupjl9tsklxc6i0d7zqzdu
28 Sep 20
The present invention provides methods and pharmaceutical compositions for treating proliferative disorders.
John A. Josey, Eli M. Wallace, Guangzhou Han
Filed: 23 Apr 19
Utility
9ow077wnb8p128gl1tjc59vb4jupvphvge8
17 Jun 20
The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer.
Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
Filed: 19 Feb 20
Utility
2ekd9qrob5o85yqv09nbfjdm7dvc
15 Apr 20
Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
Bin WANG, Hanbiao YANG, Karl BEDKE, Paul WEHN, James P. RIZZI
Filed: 28 Mar 18
Utility
xyg4uo69n4lfxkz9boaoyyaf82 9y5kkdr3df85lyotbho1t9
23 Mar 20
The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer.
Darryl David Dixon, Jonas Grina, John A. Josey, James P. Rizzi, Stephen T. Schlachter, Eli M. Wallace, Bin Wang, Paul Wehn, Rui Xu, Hanbiao Yang
Filed: 17 Oct 18
Utility
ys3csij3eirw w8zbpst4dxsgxc4wfm4upix6v6ojonzvn3v5j
23 Dec 19
The present disclosure provides methods of treating glioblastoma multiform (GBM) in a subject in need thereof.
John A. Josey
Filed: 8 Mar 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first